Adherence to medications for chronic conditions is often very low, limiting the benefit to patients, even when the medications are effective and have favorable side effect profiles.
Purpose
This article reviews some of the prior work on treatment adherence, introduces novel concepts from behavioral economics that can be used to design interventions to improve adherence, and proposes new approaches for clinical trials.
Methods
Relevant experience of the authors and insights from the literature were combined to identify key issues and propose methodological improvements. Specific examples regarding adherence to warfarin are provided.
Results
Several new approaches to trial design can be effectively applied in the context of medication adherence. These include tailored intervention strategies and sequential multiple assignment randomized trial (SMART) designs.
Limitations
While we have proposed to use these new approaches for ongoing studies of adherence in behavioral health, practical experience with their application is still somewhat limited.
Conclusions
Behavioral economics offer a variety of concepts that, when used in the design of interventions to improve adherence, may be more successful than traditional approaches. New clinical trial designs can also be adopted to improve the efficiency of studies that assess these approaches.
Get full access to this article
View all access options for this article.
References
1.
GibbonsRJAbramsJChatterjeeK. ACC/AHA 2002 guidelines update for the management of patients with chronic stable angina: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for the Management of Patients with Chronic Stable Angina). Journal of the American College of Cardiology2003; 41(1): 159-68.
2.
BaigentCKeechAKearneyPM. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet2005; 366(9493): 1267–78.
3.
Scandinavian Simvastatin Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet1994; 344(8934): 1383–9.
4.
SacksFMPfefferMAMoyeLA. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med1996; 335(14): 1001–9.
5.
DownsJRClearfieldMWeisS. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA1998; 279(20): 1615–22.
6.
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med1998; 339(19): 1349–57.
7.
RidkerPMDanielsonEFonsecaFA. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial. Lancet2009; 373(9670): 1175–82.
8.
JackeviciusCAMamdaniMTuJV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA2002; 288(4): 462–7.
9.
NewbyLKLaPointeNMChenAY. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation2006; 113(2): 203–12.
10.
BennerJSGlynnRJMogunH. Long-term persistence in use of statin therapy in elderly patients. JAMA2002; 288: 455–61.
11.
GislasonGHRasmussenJNAbildstromSZ. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J2006; 27(10): 1153–8.
12.
KulkarniSPAlexanderKPLytleBHeissGPetersonED. Long-term adherence with cardiovascular drug regimens. Am Heart J2006; 151(1): 185–91.
13.
SimpsonEBeckCRichardHEisenbergMJPiloteL. Drug prescriptions after acute myocardial infarction: Dosage, compliance, and persistence. Am Heart J2003; 145(3): 438–44.
14.
HudsonMRichardHPiloteL. Parabolas of medication use and discontinuation after myocardial infarction – are we closing the treatment gap?Pharmacoepidemiol Drug Saf2007; 16(7): 773–85.
15.
EagleKAKline-RogersEGoodmanSG. Adherence to evidence-based therapies after discharge for acute coronary syndromes: An ongoing prospective, observational study. Am J Med2004; 117(2): 73–81.
16.
HoPMMagidDJMasoudiFAMcClureDLRumsfeldJS. Adherence to cardioprotective medications and mortality among patients with diabetes and ischemic heart disease. BMC Cardiovasc Disord2006; 6: 48.
17.
BlackburnDFDobsonRTBlackburnJL. Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: A retrospective cohort study. Can J Cardiol2005; 21(6): 485–8.
18.
HoPMRumsfeldJSMasoudiFA. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med2006; 166(17): 1836–41.
19.
WeiLWangJThompsonP. Adherence to statin treatment and readmission of patients after myocardial infarction: A six year follow up study. Heart2002; 88(3): 229–33.
20.
WeiLFlynnRMurrayGDMacDonaldTM. Use and adherence to beta-blockers for secondary prevention of myocardial infarction: Who is not getting the treatment?Pharmacoepidemiol Drug Saf2004; 13(11): 761–6.
21.
RasmussenJNChongAAlterDA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA2007; 297(2): 177–86.
22.
HoPMSpertusJAMasoudiFA. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med2006; 166(17): 1842–7.
LaupacisABoysenGConnollySEzekowitzMHartRJamesK. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med1994; 154(13): 1449–57.
25.
LaupacisAAlbersGDalenJ. Antithrombotic therapy in atrial fibrillation. Chest1998; 114(5 Suppl): 579S–89S.
26.
PetersenPBoysenGGodtfredsenJAndersenEDAndersenB. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet1989; 1(8631): 175–9.
27.
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet1993; 342(8882): 1255–62.
28.
GullovALKoefoedBGPetersenP. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med1998; 158(14): 1513–21.
29.
ChiquetteEAmatoMGBusseyHI. Comparison of an anticoagulation clinic with usual medical care: Anticoagulation control, patient outcomes, and health care costs. Arch Intern Med1998; 158(15): 1641–7.
30.
GoldhaberSZ. Pulmonary embolism. N Engl J Med1998; 339(2): 93–104.
31.
BarrittDWJordanSC. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet1960; 1: 1309–12.
32.
HirshJFusterV. Guide to anticoagulant therapy. Part 2: Oral anticoagulants. American Heart Association. Circulation1994; 89(3): 1469–80.
33.
BrigdenMKayCLeAGraydonCMcLeodB. Audit of the frequency and clinical response to excessive oral anticoagulation in an out-patient population. Am J Hematol1998; 59: 22–7.
34.
KearonCGentMHirshJ. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med1999; 340(12): 901–7.
35.
LandefeldCSBeythRJ. Anticoagulant-related bleeding: Clinical epidemiology, prediction, and prevention. Am J Med1993; 95(3): 315–28.
36.
McMahanDASmithDMCareyMAZhouXH. Risk of major hemorrhage for outpatients treated with warfarin. J Gen Intern Med1998; 13(5): 311–6.
37.
LandefeldCSGoldmanL. Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy. Am J Med1989; 87(2): 144–52.
38.
DoshiJAZhuJLeeBKimmelSVolppKG. Impact of a prescription copayment increase on lipid lowering medication adherence in Veterans. Circulation2009; 119: 390–7.
39.
ChernewMEShahMRWeghA. Impact of decreasing copayments on medication adherence within a disease management environment. Health Aff2008; 27(1): 103–12.
40.
ChernewMERosenABFendrickAR. Value-based insurance design. Health Aff2007; 26(2): w195–203.
41.
TverskyAKahnemanDR. Loss aversion in riskless choice: A reference-dependent model. Q J Econ1991; 106(4): 1039–61.
42.
MarcusACKaplanCPCraneLA. Reducing loss-to-follow-up among women with abnormal Pap smears. Results from a randomized trial testing an intensive follow-up protocol and economic incentives. Med Care1998; 36(3): 397–410.
ChaissonREKerulyJCMcAvinueSGallantJEMooreRD. Effects of an incentive and education program on return rates for PPD test reading in patients with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol1996; 11(5): 455–9.
45.
KaneRLJohnsonPETownRJButlerM. A structured review of the effect of economic incentives on consumers’ preventive behavior. Am J Prev Med2004; 27(4): 327–52.
46.
HigginsSTSilvermanK. Motivating Behavior Change among Illicit Drug Abusers: Research on Contingency Management Interventions. American Psychological Association, Washington, DC, 1999.
47.
HigginsST. Applying behavioral economics to the challenge of reducing cocaine abuse. In ChaloupkaFJGrossmanMBickelWKSafferH. (eds). The Economic Analysis of Substance Use and Abuse. NBER, Cambridge, MA, 1999, pp. 157–74.
48.
SkinnerBF. Cumulative Record: A Selection of Papers (3rd edn). Meredith, New York, 1972.
49.
BainsNPickettWHoeyJ. The use and impact of incentives in population-based smoking cessation programs: A review. Am J Health Promo1998; 12: 307–20.
50.
ZeelenbergMPietersR. Consequences of regret aversion in real life: The case of the Dutch postcode lottery. Organ Behav Hum Dec2004; 93(2): 155–68.
51.
AinslieG. Specious reward: A behavioral theory of impulsiveness and impulse control. Psychol Bull1975; 82: 463–96.
52.
ThalerRH. Some empirical evidence on time inconsistency. Rev Econ Stud1981; 23: 165–80.
53.
LoewensteinGPrelecD. Anomalies in intertemporal choice: Evidence and an interpretation. Quart J Econ1992; 107: 573–97.
54.
KirbyK. Bidding on the future: Evidence against normative discounting of delayed rewards. J Exp Psychol Gen1997; 126: 54–70.
55.
CamererCHoT-H. Experience-weighted attraction learning in normal form games. Econometrica1999; 67: 837–74.
56.
LoewensteinGWeberEUHseeCKWelchN. Risk as feelings. Psychol Bull2001; 127(2): 267–86.
57.
ConnollyTButlerDU. Regret in economic and psychological theories of choice. J Behav Dec Making2006; 19(2): 148–58.
58.
ChapmanGBCoupsEJ. Emotions and preventive health behavior: Worry, regret, and influenza vaccination. Health Psychol2006; 25(1): 82–90.
59.
ThalerRHTverskyAKahnemanAS. The effect of myopia and loss aversion on risk taking: An experimental test. Quart J Econ1997; 112: 647–61.
60.
RizzoJAZeckhauserRJ. Reference incomes, loss aversion, and physician behavior. Rev Econ Stat2003; 85(4): 909–22.
61.
OsterbergLBlaschkeT. Adherence to medication. N Engl J Med2005; 353(5): 487–97.
62.
HaynesRBWangEda Mota-GomesM. A critical review of interventions to improve compliance with prescribed medications. Pat Educ Counsel1987; 10: 155–66.
63.
EpsteinLClussP. A behavioral medicine perspective on adherence to long-term medical regimens. J Consult Clin Psychol1982; 50: 950–71.
64.
ChenA. Noncompliance in community psychiatry: A review of clinical interventions. Hosp Com Psych1991; 42(3): 282–7.
65.
ZygmuntAOlsonMBoyerCMechanicD. Interventions to improve medication adherence in schizophrenia. Am J Psychiatry2002; 159: 1653–64.
66.
RuskinPEVan der WendeJClarkCR. Feasibility of using the Med-eMonitor™ system in the treatment of schizophrenia: A pilot study. Drug Infor J2003; 38: 1–8.
67.
ProchaskaJOButterworthSReddingCA. Initial efficacy of MI, TTM tailoring and HRI’s with multiple behaviors for employee health promotion. Prev Med2008; 46(3): 226–31.
68.
GreeneGWRossiSRRossiJS. Dietary applications of the stages of change model. J Am Diet Assoc1999; 99(6): 673–8.
69.
MurphySA. An experimental design for the development of adaptive treatment strategies. Stat Med2005; 24(10): 1455–81.
70.
LavoriPWDawsonRRushAJ. Flexible treatment strategies in chronic disease: Clinical and research implications. Biol Psych2000; 48(6): 605–14.
MurphySAvan der LaanMJRobinsJM and CPPRG. Marginal mean models for dynamic regimes. JASA2001; 96: 1410–23.
73.
BembomOvan der LaanMJ. Statistical methods for analyzing sequentially randomized trials. J Natl Cancer Inst2007; 99: 1577–82.
74.
CollinsLMMurphySAStrecherV. The multiphase optimization strategy (MOST) and the sequential multiple assignment randomized trial (SMART): New methods for more potent eHealth interventions. Am J Prev Med2007; 32(5 Suppl): S112–18.
75.
DengKPineauJMurphySA. Active learning for developing personalized treatment. In Proceedings of the Twenty-Seventh Conference Annual Conference on Uncertainty in Artificial Intelligence (UAI-11), Barcelona, Spain, July 14-17, AUAI Press: Corvallis, OR, 2011, pp. 161–8.
76.
DengKPineauJMurphySA. Active learning for personalizing treatment. In 2011 IEEE Symposium on Adaptive Dynamic Programming and Reinforcement Learning (ADPRL), IEEE Press: Piscataway, NJ2011, pp. 32–9.
77.
LizotteDBowlingMMurphySA. Efficient reinforcement learning with multiple reward functions for randomized controlled trial analysis. In Proceedings of the 27th International Conference on Machine Learning, Haifa, Israel, June 21-24, Omnipress: Madison, WI, 2010, pp. 695–702.
78.
ShawJ. Is it acceptable for people to be paid to adhere to medication? No. BMJ2007; 335: 233.
79.
HalpernSDMadisonKMVolppKG. Patients as mercenaries? The ethics of using financial incentives in the war on unhealthy behaviors. Circ Cardiovasc Qual Outcomes2009; 2: 514–6.
